Jump to top menu Jump to main menu Jump to content


Fundamental, translational and applied research into normal and malignant hematopoiesis, stem cell transplantation, developmental diagnostics and therapeutics, and hemostasis and thrombosis.

About our department

Our research

At the department of Hematology we are dedicated to improving the diagnosis and treatment of patients with hematological diseases. We perform basic and translational research to generate insight into the pathobiology of hematological diseases, and translate these findings into novel treatments for our patients.

In addition, we direct a wide variety of clinical studies, closely linked to our preclinical programs. These clinical studies deal with the development of molecular diagnostics, advancement of allogeneic stem cell transplantation, circumvention of drug-resistance to chemotherapy as well as a broad range of clinical phase I to phase III trials for a variety of hematological diseases.

For more information on specific research lines please select a principle investigator from the list below or select a particular hematological disease in the list of research lines.

For more information on clinical care for patients with hematological diseases please see our clinical homepage.

Follow this link to see all our studies.

Principal Investigators

Research lines


News, events and awards

Our news


Virtual Hematology Lectures Fall 2021

Time: Mondays 16:00 hrs / 04.00 PM CET
Location: Zoom 
Contact: Prof Dr Ruud Delwel, h.delwel@erasmusmc.nl, Mrs. Tessa Mannee, t.mannee@erasmusmc.nl
Duration: 1 hour
Cost: Free of charge & no registration required
Webinar ID: 941 4638 9345
Zoom link: https://zoom.us/j/94146389345

06 September 2021

Alexander van Oudenaarden, Hubrecht Institute, Utrecht, The Netherlands

Ribosomal profiling in single cells

13 September 2021

Len Zon, Boston Children’s Hospital, Boston, U.S.A.

Stem cell clonality and the niche

20 September 2021

Ravi Majeti, Stanford University, Stanford, U.S.A.

Stem cells in human AML

27 September 2021

Elli Papaemmaniul, Memorial Sloan Kettering Cancer Center, New York, U.S.A.

Genomic studies of myeloid disease

04 October 2021

Jorge di Paola, Washington University School of Medicine, Saint Louis, U.S.A.

Molecular mechanisms of ETV6 associated thrombocytopenia and cancer predispositione

11 October 2021

Nicoletta Sorvillo, University of Bern, Bern, Switzerland

NETs and extracellular citrullination: friends or foes in vascular health?

18 October 2021

Christopher Ott, Massachusetts General Hospital, Boston, U.S.A.

Chemical modulation of enhancers

25 October 2021

Marina Cavazzana, Necker Hospital, Paris, France

Gene therapy in genetic disorders

01 November 2021

John Welch, Washington University School of Medicine, Saint Louis, U.S.A.

Decitabine responses in AML/MDS

08 November 2021

Dave Bodine, National Human Genome Research Institute, Bethesda, U.S.A.

A practical and theoretical understanding of Diamond Blackfan anemia revealed by genomics

15 November 2021

Marjorie Brand, Ottawa Hospital Research Institute, Ottawa, Canada

Cell fate decisions in hematopoiesis and T-cell leukemogenesis

22 November 2021

Walter Kahr, The Hospital for Sick Children & University of Toronto, Toronto, Canada

Insights into megakaryocyte development from inherited platelet disorders

29 November 2021

Scott Armstrong, Dana-Farber Cancer Institute, Boston, U.S.A.

Targeting epigenetic mechanisms in leukemia

06 December 2021

Amanda Fisher, MRC London Institute of Medical Sciences & Imperial College London, London, U.K.

Epigenetic memory

20 December 2021

Madhav Dhodapkar, Emory University, Atlanta, U.S.A.

Early tumor immune interactions and opportunities for prevention in plasma cell malignancies


Grant Department Hematology ErasmusMC for single cell analyses in hematologic malignancies

The Hematology department has received a grant of €100.000 from the Stichting Leukemie (www.leukemie.nl) for single cell analysis of hematological malignancies, in particular acute myeloid leukemia (AML).

Peter Valk Award Department Hematology

AML is an example of a heterogeneous group of hematologic malignancies with a variable response to therapy. The heterogeneity of AML is illustrated by the different (combinations of) mutations that occur with AML. Based on these mutations the prognosis of the AML patient can be estimated. However, despite the fact that prognostics in AML has greatly improved in recent decades, there is still much to be learned.

Residual disease during therapy of a haematological malignancy is a good predictor for getting recurrence of disease. We have recently demonstrated that the use of next generation sequencing in residual disease detection greatly improves the quantitative prediction of a recurrence (M. Jongen et al., NEJM 378, 2018).

The analyses in the above study were performed on the bulk of the AML cells. Analysis of DNA abnormalities at the level of a single cell will ultimately be necessary to determine which cells within a heterogeneous population of cells are critically important for the return of the AML. The grant from the Stichting Leukemie will be used to purchase equipment for the analysis of residual disease in AML at the single cell level.